Update on cardiac biomarkers

Laboratory Medicine

Volumn 37, Issue 10, 2006, Pages 597-605

  Carreiro Lewandowski, Eileen ^a  

^a UNIVERSITY OF MASSACHUSETTS DARTMOUTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; CD40 LIGAND; CREATINE KINASE MB; FATTY ACID BINDING PROTEIN; MATRIX METALLOPROTEINASE; MYELOPEROXIDASE; MYOGLOBIN; PHOSPHOLIPASE A2; PLACENTAL GROWTH FACTOR; PREGNANCY ASSOCIATED PROTEIN; TROPONIN I; TROPONIN T;

ACUTE CORONARY SYNDROME; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; REVIEW; RISK ASSESSMENT; TISSUE NECROSIS; UNSTABLE ANGINA PECTORIS;

EID: 33749500413     PISSN: 00075027     EISSN: None     Source Type: Journal    
DOI: 10.1309/LYJ8PL6A7A4FJWCA     Document Type: Review

References (74)

1. Alpert JS, Thygesen K, Antman E, et al. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cadiol. 2000;36:959-969.
2. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 Guideline Update for the Management of Patients With Unstable Angina and Non-ST-Segment Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients with Unstable Angina). Available at: http://www.acc.org/clinical/ guidelines/unstable/unstable.pdf Accessed December 31, 2005.
3. American Heart Association. Heart Disease and Stroke Statistics-2005 Update. Dallas: American Heart Association; 2005.
4. Libby, P. Inflammation in artherosclerosis. Nature. 2002;420:868-874.
5. Fritsma, G. Laboratory results that predict arterial thrombosis. Clinical Laboratory Science. 2001;14:262-268.
6. Goldman L, Cook EF, Brand DA, et al. A computer protocol to predict myocardial infarction in emergency department patients with chest pain. N Engl J Med. 1988;318:797-803.
7. Lee TH, Juarez G, Cook EF, et al. Ruling out acute myocardial infarction. A prospective multi-center validation of a 12-hour strategy for patients at low risk. N Engl J Med. 1991;324:1239-1246.
8. Prina LD, Decker WW, Weaver AL, et al. Outcome of patients with a final diagnosis of chest pain of undetermined origin admitted under the suspicion of acute coronary syndrome: a report for the Rochester Epidemiology Project. Ann Emerg Med. 2004;43:59-67.
9. Manini AF, Gisondi MA, van der Vlugt TM, et al. Adverse cardiac events in emergency department patients with chest pain six months after a negative inpatient evaluation for acute coronary syndrome. Acad Emerg Med. 2002;9:896-902.
10. Mitchel AM, Brown MD, Menown IBA, et al. Novel protein markers of acute coronary syndrome complications in low-risk out patients: A systematic review of potential use in the emergency department. Clin Chem. 2005;51:2005-2012.
11. Wu AH, Apple FS, Gibler WB, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines. Recommendations for the use of cardiac markers in coronary artery disease. Clin Chem. 1999;45:1104-1121.
12. Mockel M, Gerhardt W, Heller G Jr, et al. Validation of NACB and IFCC guidelines for the use of cardiac markers for early diagnosis and risk assessment inpatients with acute coronary syndromes. Clin Chim Acta. 2001;303:167-179.
13. Brogan GX Jr, Friedman S, McCuskey C, et al. Evaluation of a new rapid quantitative immunoassay for serum myoglobin versus CK-MB for ruling out acute myocardial infarction in the Emergency Department. Ann Emerg Med. 1994;24:665-671.
14. Bock MD, Brogan GX, McCuskey, CF, et al. Evaluation of ck-mb isoform analysis for early diagnosis of myocardial infarction. J Emerg Med. 1999;17:75-79.
15. Puleo PR, Meyer D, Wathen C, et al. Use of a rapid assay of subforms of creatine kinase MB to diagnose or rule out myocardial infarction. N Engl J Med. 1994;331:561-566.
16. Antman E. Decision making with cardiac troponin tests. N Engl J Med. 2002;346:2079-2082.
17. Eriksson S, Halenius H, Pulkki I, et al. Negative interference in cardiac troponin I immunoassays by circulating troponin autoantibodies. Clin Chem. 2005;51:839-847.
18. Panteghini M. Standardization of cardiac troponin I measurements: The way forward? Clin Chem. 2005;51:1594-1597.
19. Panteghini M, Pagani F, Yeo KT, et al. Evaluation of imprecision for cardiac troponin assays at low-range concentrations. Clin Chem. 2004;50:327-332.
20. Waxman D, Buchwald JM, Shappert J, et al. Acad Emerg Med. 2004;11:505.
21. Roongsritong C, Warraich I, Bradley C. Common causes of troponin elevations in the absence of acute myocardial infarction: Incidence and clinical significance. Chest. 2004;125:1877-1884.
22. Babuin L, Jaffe AS. Troponin: The biomarker of choice for the detection of cardiac injury. CMAJ. 2005;173:1191-1202.
23. de Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular diseases. Lancet. 2003;362:316-322.
24. de Lemos JA, Morrow DA. Brain natriuretic peptide measurement in acute coronary syndromes: Ready for clinical application? Circulation. 2002;106:2868-2870.
25. Omland T, Aakvaag A, et al. Plasma brain natriuretic peptide as an indicator of ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation. 1996;93:1963-1969.
26. Wang TJ, Larson MG, Levy D, et al. Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med. 2004;350:655-663.
27. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
28. Logeart D, Saudubray C, Beyne P, et al. Comparative value of Doppler echocardiography and B-type natriuretic peptide assay in the etiologic diagnosis of acute dyspnea. J Am Coll Cardiol. 2002;40:1794-800.
29. Silver MA, Maisel A, Yancy CW, et al. BNP consensus panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment, monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. Congest Heart Fail. 2004;10:1-30.
30. Bhalla V, Willis S, Maisel AS. B-type natriuretic peptide; the level and the drug-partners in the diagnosis and management of congestive heart failure. Congest Heart Fail. 2004;10:1-27.
31. Maisel AS, McCord J, Nowak RM, et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the breathing not properly multinational study. J Am Coll Cardiol. 2003;41:2010-2017.
32. Lainchbury JG, Campbell E, Frampton AM, et al. Brain natriuretic peptide and n-terminal brain natriuretic peptide in the diagnosis of heart failure in patients with acute shortness of breath. J Am Coll Cardiol. 2003;42:728-735.
33. Mueller T, Gegenhuber A, Poelz W, et al. Diagnostic accuracy of B type natriuretic peptide and amino terminal proBNP in the emergency diagnosis of heart failure. Heart. 2005;91:606-612.
34. Wivott SD, deLemos JA, Morrow DA. Pathophysiology, prognostic significance and clinical utility of B-type natriuretic peptide in acute coronary syndromes. Clin Chim Acta. 2004;346:119-128.
35. Givertz MM, Braunwald E. Neurohormones in heart failure: Predicting outcomes, optimizing care. Eur Heart J. 2004;25:281-282.
36. Magnussen M, Oleander O, Israelaaon B, et al. Elevated plasma levels of NT-proBNP in patients with type 2 diabetes without overt cardiovascular disease. Diabetes Care. 2004;27:1929-1935.
37. Kemperman H, van den Berg M, Kirkels H, et al. B-type natriuretic peptide (BNP) and N-terminal proBNP in patients with end-stage heart failure supported by a left ventricular assist device. Clin Chem. 2004;50:1670-1672.
38. Mundy BJ, McCord J, Nowal RM, et al. B-type natriuretic peptide levels are inversely related to body mass index in patients with heart failure. J Am Coll Cardiol. 4l;suppl A: 158A.
39. Mueller T, Gegenhuber A, Dieplinger B, et al. Capability of B-type natriuretic peptide (BNP) and amino-terminal proBNP as indicators of cardiac structural disease in asymptomatic patients with systemic arterial hypertension. Clin Chem. 2005;51:2245-2251.
40. Apple FS, Panteghini M, Ravkilde J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem. 2005;51:486-993.
41. Riker PM, Cook N. Clinical usefulness of very high and very low levels of C-reactive protein across the full range of Framingham risk scores. Circulation. 2004;109:1955-1959.
42. Pearson T, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: Application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
43. Heeschen C, Hamm CW, Bruemmer J, et al. The chimeric c7E3 antiplatelet therapy in unstable angina refractory to standard treatment (CAPTURE) investigators. Predictive value of C-reactive protein and troponin T in patients with unstable angina: a comparative analysis. J Am Coll Cardiol. 2000;35:1535-1542.
44. Di Napoli M, Papa F, Bocola V. C-reactive protein in ischemic stroke: An independent prognostic factor. Stroke. 2001;32:917-924.
45. Zebrack JS, Anderson JL, Maycock CA, et al. Usefulness of high-sensitivity C-reactive protein in predicting long-term risk of death or acute myocardial infarction in patients with unstable or stable angina pectoris or acute myocardial infarction. Am J Cardiol. 2002;89:145-149.
46. Rossi E, Biasucci LM, Citterio F, et al. Risk of myocardial infarction and angina in patients with severe peripheral vascular disease: Predictive role of C-reactive protein. Circulation. 2002;105:800-803.
47. Nawsad S, Svane B, Hansson L, et al. Response of serum C-reactive protein to percutaneous coronary interventions has prognostic value. Clin Chem. 2005;51:2124-2130.
48. Nicholls SJ, Hazen SL. Myeloperoxidase and cardiovascular disease. Arteriosclerosis Thrombosis Vascular Biol. 2005;25:1102-1111.
49. Askari AT, Brennan ML, Zhou X, et al. Myeloperoxidase and plasminogen activator inhibitor 1 play a central role in ventricular remodeling after myocardial infarction. J Exp Med. 2003;197:615-624.
50. Kutter D, Devaquet P, Vanderstocken G, et al. Consequences of total and subtotal myeloperoxidase deficiency: Risk or benefit? Acta Haematol. 2000;104:10-15.
51. Brennan, ML, Penn MS, Van Lente F, et al. Prognostic value of myeloperoxidase in patients with chest pain. New Engl J Med. 2003;346:1595-1604.
52. Apple FS, Wu AH, Mair J, et al. Future biomarkers for detection of ischemia and risk stratification in acute coronary syndrome. Clin Chem. 2005;51:810-824.
53. Squire IB, Evans J, Ng LL, et al. Plasma MMP-9 amd MMP-2 following acute myocardial infarction in man: Correlation with echo cardiographic and neurohormonal parameters of left ventricular dysfunction. J Card Fail. 2004;10:328-333.
54. Lobo RA. Evaluation of cardiovascular event rates with hormone therapy in healthy, early postmenopausal women: results from 2 large clinical trials. Arch Intern Med. 2004;164:482-484.
55. Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
56. Wald NJ, George L, Smith D, et al. Serum screening for Down's syndrome between 8 and 14 weeks of pregnancy for the International Prenatal Reseach Group. Br J Obstet Gynaecol. 1996;103:407-412.
57. Conti E, Carrozza C, Capoluongo E, et al. Insulin-like growth factor-1 as a vascular protective factor. Circulation. 2004;110:2260-2265.
58. Cosin-Sales J, Kaski JC, Christiansen M, et al. Relationship among pregnancy associated plasma protein-A levels, clinical characteristics and coronary artery disease extent in patients with chronic stable angina. Eur Heart. 2005;26:2093-2098.
59. Bayes-Genis A, Conover CA, Overgaard MI, et al. Pregnancy-associated plasma protein A as a marker of acute coronary syndromes. N Engl J Med. 2001;345:1022-1029.
60. Autiero M, Luttun A, Tjwa M, et al. Placental growth factor and its receptor, vascular endothelial growth factor receptor-1: novel targets for stimulation of ischemic tissue revascularization and inhibition of angiogenic and inflammatory disorders. J Thromb Haemost. 2003;1:1356-1370.
61. Heeschen D, Dimmeler S, Fichtlscherer S, et al. Prognostic value of placenta! growth factor in patients with acute chest pain. JAMA. 2004;291:435-441.
62. Garrido IP, Roy D, Calvinao R, et al. Comparison of ischemia-modified albumin levels in patients undergoing percutanous coronary intervention for unstable angina pectoris with versus without coronary collaterals. Am J Cardiol. 2004;93:88-90.
63. Roy D, Quiles J, Sharma R, et al. Ischemia-modified albumin concentrations in patients with peripheral vascular disease and exercise-induced skeletal muscle ischemia. Clin Chem. 2004;50:1656-1660.
64. Azzazy HM, Pelser MM, Christenson RH. Unbound free fatty acids and heart-type fatty acid-binding protein: diagnostic assays and clinical applications. Clin Chem. 2006;52:19-29.
65. Young AC, Scapin G, Kromminga A, et al. Structural studies on human muscle fatty acid binding protein at 1.4 Å resolution: binding interaction with three C18 fatty acids. Structure. 1994;2:523-534.
66. Okamoto F, Sohmiya K, Ohkaru Y, et al. Human heart-type cytoplasmic fatty acid-binding protein (H-FABP) for the diagnosis of acute myocardial infarction. Clinical evaluation of H-FABP in comparison with myoglobin and creatine kinase isoenzyme MB. Clin Chem. 2000;38:231-238.
67. Pelsers MM, Hanhoff T, Van der Voort D, et al. Brain- and heart-type fatty acid-binding proteins in the brain: tissue distribution and clinical utility. Clin Chem. 2004;50:1568-1575.
68. 2 as an independent predictor of coronary heart disease. N Engl J Med. 2000;343:1148-1155.
69. Gazi I, Lourida ES, Filippatos T, et al. Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma. Clin Chem. 2005;51:2264-2273.
70. Chambless LE, Folson AR, Davis V, et al. Risk factors for progression of common carotid atheroclerosis; the atherosclerosis risk in communities study, 1987-1998. Epidemiol. 2002;155:38-47.
71. Wu AH. Markers for early detection of cardiac diseases. Scand J Clin Lab Invest. 2005;65(suppl 240):112-121.
72. Danne O, Mockel M, Leuders C, et al. Prognostic implications of elevated whole blood choline levels in acute coronary syndrome. Am J Cardiol. 2003;91:1060-1067.
73. Christodoulides N, Floriano P, Acosta S, et al. Toward the development of a lab-on-a-chip dual-function leukocyte and C-reactive protein analysis method for the assessment of inflammation and cardiac risk. Clin Chem. 2005;51:2391-2395.
74. Lee DH, Jacobs DR, Gross M, et al. γ-glutamyltransferase is a predictor of incident diabetes and hypertension: The Coronary Artery Risk Development in Young Adults (CARDIA) Study. Clin Chem. 2003;49(8):1358-1366.